- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04457960
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Participants and Multiple Dose Study in Participants With Ulcerative Colitis to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-66525433
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite Research Organisation GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For Part 1 and Part 2, healthy volunteers
- Have a body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m^2) (BMI = weight/height), inclusive, and a body weight of no less than 50 kilogram (kg) and maximum weight of 100 kg
- Have normal bowel movements, ranging from 1 to 3 times daily to every other day and have normal consistencies according to the Bristol Stool Scale, ranging from 3 to 5 at admission
For Part 3, participants with ulcerative colitis (UC)
- Have a clinical diagnosis of UC at least 3 months before screening
- Have moderately to severely active UC, defined as a Week 0 mayo score of 6 to 12, inclusive, based on central read of the video endoscopy performed during the screening
- Have a greater than or equal to (>=) 2 endoscopy subscore of the Week 0 mayo score based on central read of the video endoscopy performed during the screening
Exclusion Criteria:
For Part 1 and Part 2, healthy volunteers
- History of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to antisense oligonucleotides, JNJ-66525433 or its excipients
For Part 3, participants with UC
- Has UC limited to the rectum only or to <20 centimeter (cm) of the colon evaluated by endoscopy at screening
- Presence of a stoma
- Presence or history of a fistula at any time
COVID-related
- If a participant is excluded due to recent Coronavirus disease (COVID-19) related features, the reason for screen failure should be documented in the case report form under the exclusion criterion of having a condition for which participation would not be in the participant's interest or could confound study assessments
- The field of COVID-related testing (for presence of, and immunity to, the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] virus) is rapidly evolving. Additional testing may be performed as part of screening and/or during the study if deemed necessary by the investigator and in accordance with current regulations / guidance from authorities / standards of care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JNJ-66525433
Participants will receive JNJ-66525433 in increasing dose level 1 to dose level 4 in Parts 1, 2, and dose level 3 in part 3.
|
Participants will receive JNJ-66525433 oral capsules.
|
Placebo Comparator: Placebo
Participants will receive matching placebo in Parts 1, 2 and 3.
|
Participants will receive matching placebo oral capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1, 2 and 3: Number of Participants with Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability
Time Frame: Up to 224 Days
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
Any AE occurring at or after the initial administration of study intervention through the day of last dose plus 30 days will be considered as TEAE.
|
Up to 224 Days
|
Part 1, 2 and 3: Number of Participants with Vital Sign Abnormalities
Time Frame: Up to 224 Days
|
Number of participants with vital sign abnormalities (temperature), pulse/heart rate, respiratory rate and blood pressure) will be reported.
|
Up to 224 Days
|
Part 1, 2 and 3: Number of Participants with Physical Examination Abnormalities
Time Frame: Up to 224 Days
|
Number of participants with physical examination abnormalities will be reported.
|
Up to 224 Days
|
Part 1, 2 and 3: Number of Participants with Hematology Laboratory Abnormalities
Time Frame: Up to 224 Days
|
Number of participants with hematology laboratory abnormalities will be reported.
|
Up to 224 Days
|
Part 1, 2 and 3: Number of Participants with Chemistry Laboratory Abnormalities
Time Frame: Up to 224 Days
|
Number of participants with chemistry laboratory abnormalities will be reported.
|
Up to 224 Days
|
Part 1, 2 and 3: Number of Participants with Urinalysis Laboratory Abnormalities
Time Frame: Up to 224 Days
|
Number of participants with abnormalities in urinalysis will be reported.
|
Up to 224 Days
|
Part 2 and 3: Number of Participants with Abnormalities in High Sensitivity C- Reactive Protein (hs-CRP)
Time Frame: Up to 224 Days
|
Number of participants with abnormalities in hs-CRP will be reported using a validated, high sensitivity CRP assay.
|
Up to 224 Days
|
Part 2 and 3: Number of Participants with Abnormalities in Fecal Calprotectin
Time Frame: Up to 224 Days
|
Assays for fecal calprotectin will be performed using a validated method.
|
Up to 224 Days
|
Part 2 and 3: Incidence of Enteric Pathogens in Stool Samples
Time Frame: Up to 224 Days
|
Stool culture and Clostridium difficile toxin assay will be used for enteric pathogen assessment.
|
Up to 224 Days
|
Part 1, 2 and 3: Number of Participants with Electrocardiogram (ECG) Abnormalities
Time Frame: Up to 224 Days
|
Number of participants with ECG abnormalities will be reported.
|
Up to 224 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1, 2 and 3: Plasma Concentrations of JNJ-66525433
Time Frame: Up to 224 Days
|
Plasma concentrations of JNJ-66525433 will be reported.
|
Up to 224 Days
|
Part 1: Plasma Concentrations of JNJ-66525433 After Fasted or Fed Dosing
Time Frame: Up to Day 14
|
Plasma concentrations of JNJ-66525433 after fasted or fed dosing will be reported.
|
Up to Day 14
|
Part 3: Mayo Score
Time Frame: Up to Day 84
|
Mayo scoring system is used for assessment of ulcerative colitis activity.
The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings) each ranges from 0 to 3. The Mayo score is calculated as the sum of these 4 subscores and can range between 0 and 12, where higher score indicates severe disease.
|
Up to Day 84
|
Part 3: Partial Mayo Score
Time Frame: Up to Day 70
|
Partial Mayo score is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, and physician's global assessment) and ranges from 0 to 9 points.
Higher score indicates severe disease.
|
Up to Day 70
|
Part 3: Endoscopic Subscore
Time Frame: Up to Day 84
|
Endoscopy sub-score ranges from 0 to 3 where; 0 = normal or inactive disease; 1 = mild disease (erythema, decreased vascular pattern, mild friability); 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions); 3 = severe disease (spontaneous bleeding, ulceration).
|
Up to Day 84
|
Part 3: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
Time Frame: Days 1, 7, 14, 28, 43, 70 and 84
|
IBDQ18 is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).
Scores range from 32 to 224, with higher scores indicating better outcomes.
|
Days 1, 7, 14, 28, 43, 70 and 84
|
Part 2 and 3: Target Engagement of Messenger Ribonucleic Acid (mRNA) Levels
Time Frame: Up to 182 Days
|
Levels of mRNA knockdown will be reported to assess target engagement in biopsy tissue by dose level over time.
|
Up to 182 Days
|
Part 2 and 3: Tissue Biopsy JNJ-66525433 Concentrations
Time Frame: Up to 182 Days
|
Tissue biopsy concentrations of JNJ-66525433 will be reported.
|
Up to 182 Days
|
Plasma Concentrations of JNJ-66525433 After Two Meal Timing Conditions
Time Frame: Up to 22 Days
|
Plasma concentrations of JNJ-66525433 after two meal timing condition (fed state to modified fasted state) will be reported (if conducted).
|
Up to 22 Days
|
Faecal Concentrations of JNJ-66525433 After Two Meal Timing Conditions
Time Frame: Predose, up to 120 hours postdose
|
Stool assessment will be done to characterize the presence of JNJ-66525433 after two meal timing conditions (fed state to modified fasted state) will be reported (if conducted).
|
Predose, up to 120 hours postdose
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108764
- 2018-003743-29 (EudraCT Number)
- 66525433IBD1001 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on JNJ-66525433
-
Janssen Research & Development, LLCRecruitingLymphoma, Non-HodgkinDenmark, Israel, Spain, Australia
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Johnson & Johnson Enterprise Innovation Inc.RecruitingAdvanced Solid TumorsUnited States